

Detection and Dynamic Changes of *EGFR* Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony Mok¹, Yi-Long Wu², Jin Soo Lee³, Chong-Jen Yu⁴, Virote Sriuranpong⁵, Jennifer Sandoval-Tan⁶, Guia Ladrera⁷, Sumitra Thongprasert⁸, Vichien Srimuninnimit⁹, Meilin Liao¹⁰, Yunzhong Zhu¹¹, Caicun Zhou¹², Fatima Fuerte¹³, Benjamin Margono¹⁴, Wei Wen¹⁵, Julie Tsai¹⁵, Matt Truman¹⁶, Barbara Klughammer¹⁷, David S. Shames¹⁸, and Lin Wu¹⁵

Abstract

Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based *EGFR* mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study.

Experimental Design: Patients were randomized to receive six cycles of gemcitabine/platinum plus sequential erlotinib or placebo. *EGFR* mutation testing was performed using the cobas tissue test and the cobas blood test (in development). Blood samples at baseline, cycle 3, and progression were assessed for blood test detection rate, sensitivity, and specificity; concordance with matched tumor analysis ($n = 238$), and correlation with progression-free survival (PFS) and overall survival (OS).

Results: Concordance between tissue and blood tests was 88%, with blood test sensitivity of 75% and a specificity of 96%. Median

PFS was 13.1 versus 6.0 months for erlotinib and placebo, respectively, for those with baseline *EGFR* mut⁺ cfDNA [HR, 0.22; 95% confidence intervals (CI), 0.14–0.33, $P < 0.0001$] and 6.2 versus 6.1 months, respectively, for the *EGFR* mut⁻ cfDNA subgroup (HR, 0.83; 95% CI, 0.65–1.04, $P = 0.1076$). For patients with *EGFR* mut⁺ cfDNA at baseline, median PFS was 7.2 versus 12.0 months for cycle 3 *EGFR* mut⁺ cfDNA versus cycle 3 *EGFR* mut⁻ patients, respectively (HR, 0.32; 95% CI, 0.21–0.48, $P < 0.0001$); median OS by cycle 3 status was 18.2 and 31.9 months, respectively (HR, 0.51; 95% CI, 0.31–0.84, $P = 0.0066$).

Conclusions: Blood-based *EGFR* mutation analysis is relatively sensitive and highly specific. Dynamic changes in cfDNA *EGFR* mutation status relative to baseline may predict clinical outcomes. *Clin Cancer Res*; 21(14); 3196–203. ©2015 AACR.

¹State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong. ²Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. ³National Cancer Center, Goyang, Korea. ⁴National Taiwan University Hospital, Taipei, Taiwan. ⁵The King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand. ⁶Philippine General Hospital, Manila, Philippines. ⁷Lung Centre of the Philippines, Quezon City, Philippines. ⁸Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. ⁹Siriraj Hospital, Bangkok, Thailand. ¹⁰Shanghai Lung Tumour Clinical Medical Center, Shanghai Chest Hospital, Shanghai, China. ¹¹Beijing Chest Hospital, Beijing, China. ¹²Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. ¹³Rizal Medical Center, Pasig City, Philippines. ¹⁴Dokter Soetomo Hospital, Surabaya, Indonesia. ¹⁵Roche Molecular Systems, Inc., Pleasanton, California. ¹⁶Roche Products Ltd, Dee Why, Australia. ¹⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland. ¹⁸Oncology Biomarker Development, Genentech Inc., San Francisco, California.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Phone: 8620-83877855; Fax: 8620-83827712; E-mail: syylwu@live.cn

doi: 10.1158/1078-0432.CCR-14-2594

©2015 American Association for Cancer Research.

Introduction

Activating *EGFR* mutations are the standard predictive biomarker for selection of first-line *EGFR* tyrosine-kinase inhibitors (TKI) for patients with advanced non-small cell lung cancer (NSCLC; refs. 1–9). However, *EGFR* mutation analysis is not always possible for all patients (often due to suboptimal quantity or quality of biopsies, or facilities lacking the necessary technology or expertise), therefore treatment decisions are often made when *EGFR* mutation status is unknown (10, 11). Circulating-free (cf) tumor DNA in the blood could provide a potential alternative to tumor-derived samples as a source of DNA for *EGFR* mutation analysis (12).

Previous studies have shown the feasibility of investigating *EGFR* mutation status in cfDNA; however, most of these prior studies are retrospective, and the detection and concordance rates reported have varied greatly. Bai and colleagues reported a detection rate of 34.3% and concordance of 78% to 79.7% using a denaturing high-performance liquid chromatography detection technique in unselected Chinese patients with advanced NSCLC treated with first-line chemotherapy. Patients with *EGFR* mutations in plasma had significantly longer progression-free survival (PFS) than those without mutations in plasma (13). Kimura and

Translational Relevance

Several studies have retrospectively assessed blood-based analysis of *EGFR* mutation status; however, a prospective analysis of blood-based *EGFR* mutation assessment was needed. The prospective analysis of blood-based assessment of *EGFR* mutation status in the FASTACT-2 trial showed that this was a relatively sensitive and highly specific method for mutation detection. In those with blood-based *EGFR* mutation-positive results at baseline, the dynamic change in *EGFR* status in blood samples was linked with efficacy outcomes. Those with *EGFR* mutation-negative assessment at cycle 3 had better efficacy outcomes in terms of PFS and OS than those whose samples were still *EGFR* mutation positive at cycle 3. This suggests that the dynamic change in blood-based *EGFR* status could be used to predict benefit of further treatment with erlotinib. These current results show that plasma cfDNA is a potential source material for *EGFR* mutation analysis in clinical practice for those unable to provide tissue-based samples.

colleagues showed a detection rate of 16.7% and a concordance with tumor mutation status of 92.9% using Scorpion-ARMS in patients treated with gefitinib (14). This method had a sensitivity of 78.9% and a specificity of 97.0%. Patients with *EGFR* mutations in both tumor and blood samples had significantly longer median PFS than patients without blood-based mutations ($P = 0.044$; ref. 14). A detection rate of 23.7% and concordance of 66.3% were reported by Goto and colleagues, as assessed by Scorpion-ARMS in a Japanese subgroup of patients from the IPASS study (15). Sensitivity and specificity were 43.1% and 100%, respectively. Recently, a Scorpion-ARMS methodology was used in a first-line, single-arm study of gefitinib, resulting in a concordance rate of 94.3%, with sensitivity of 65.7% and specificity of 99.8% (16). Kim and colleagues used peptide nucleic acid-mediated PCR clamping to analyze *EGFR* mutations in blood samples, resulting in a detection rate of 16.7%, concordance of 27.5%, and sensitivity of 20.7% (17). Couraud and colleagues have developed multiplex PCR-based assays to identify *EGFR* mutations from plasma, resulting in concordance with tumor samples of 81% for exon 19 mutations and 97% for exon 21 mutations (18). Recent studies have also shown the feasibility of using digital droplet PCR for plasma-based assessment of mutations (19). The variable outcomes of these studies are explained by the different technologies used, lack of standardization, and the absence of prospective clinical and biomarker data. In addition, these studies did not evaluate the utility of measuring pharmacodynamic changes in cfDNA *EGFR* mutation levels during treatment, which could better inform clinical decision-making and improve outcomes.

FASTACT-2 (First-line Asian Sequential Tarceva And Chemotherapy Trial), a randomized, phase III study, was designed to confirm the promising findings from the phase II FASTACT study assessing an intercalated combination of erlotinib and platinum-based chemotherapy for the treatment of NSCLC (20, 21). The study met its primary endpoint; however, the treatment effect was largely driven by the approximately 40% of patients with *EGFR* mutation-positive tumors: median PFS was 16.8 versus 6.9 months for the erlotinib versus placebo arm, respectively (HR, 0.25; $P < 0.0001$), whereas median overall survival (OS) was 31.4 versus 20.6 months for erlotinib versus placebo, respectively (HR,

0.48; $P = 0.0092$) in patients with *EGFR* mutation-positive tumors (21).

This analysis prospectively explored *EGFR* mutation analysis of baseline tumor and blood samples from FASTACT-2. The primary objective was to define the diagnostic utility of blood-based *EGFR* mutation detection using a real-time PCR-based blood test, for the detection of activating *EGFR* mutations from cfDNA. The secondary objective was to explore the predictive value of cfDNA *EGFR* mutation status at baseline and the dynamic change in mutation status during therapy, in relation to clinical outcomes.

Materials and Methods

Study design

FASTACT-2 was a multicenter, randomized, placebo-controlled, double-blind, phase III study of intercalated erlotinib or placebo with gemcitabine plus platinum (carboplatin or cisplatin) followed by maintenance erlotinib or placebo as first-line treatment in patients with stage IIIB/IV NSCLC (21). All patients provided written informed consent before any study-related procedure, including provision of samples for biomarker testing.

Procedures

Full methodology has been previously described (21). Briefly, patients were randomized 1:1 by interactive internet response system to receive six cycles of gemcitabine (1,250 mg/m² intravenously on days 1 and 8 of a 4-week cycle) plus platinum (carboplatin 5×AUC, or cisplatin 75 mg/m² intravenously on day 1 of a 4-week cycle), plus either sequential erlotinib (150 mg/day orally; erlotinib arm) or placebo (placebo arm) on days 15 to 28 of each cycle. Those who did not progress during the six cycles of sequential treatment continued to receive erlotinib or placebo until disease progression (PD), unacceptable toxicity, or death. At PD, treatment was unblinded and patients in the placebo group could receive open-label erlotinib; patients in the erlotinib group could receive further treatment at the discretion of the investigator.

Biomarker analysis

Tumor tissue samples from either initial diagnosis, diagnosis of advanced/metastatic disease, or resection or biopsy 14 days before first study dose, were required. Blood for plasma and serum isolation was collected according to standard procedures at baseline (within 7 days before first study dose), at day 1 of cycle 3 (C3; before C3 study treatment) and at the time of PD. Samples will be stored for up to 5 years after the final study database lock, at which time they will be destroyed.

Retrospective *EGFR* mutation testing of formalin-fixed paraffin-embedded tissue (FFPET) and plasma/serum was performed with two allele-specific PCR assays: the cobas 4800 FFPET test utilized as per manufacturer's instructions (Roche Molecular Systems Inc.) and the cobas 4800 blood test (in development, provided by Roche Molecular Systems Inc.). The *EGFR* blood test was performed using 2 mL of blood. Each patient's blood samples from all three time points were tested. For approximately 80% of the baseline samples, it was necessary to combine one aliquot of serum with the plasma sample to achieve the required 2 mL (the blood assay is highly concordant between serum and plasma samples, data on file). A total of 2 mL of blood was used for cfDNA extraction using the cobas cell-free DNA Purification Kit (in development; ref. 22). The cfDNA was eluted in 100 μ L, 75 μ L

Table 1. Baseline characteristics stratified by tumor or cfDNA *EGFR* mutation status at baseline

N (%)	Tumor <i>EGFR</i> mut ⁺ (N = 97)		Tumor <i>EGFR</i> mut ⁻ (N = 136)		cfDNA <i>EGFR</i> mut ⁺ (N = 144)		cfDNA <i>EGFR</i> mut ⁻ (N = 303)	
	GC+E (N = 49)	GC+P (N = 48)	GC+E (N = 69)	GC+P (N = 67)	GC+E (N = 72)	GC+P (N = 72)	GC+E (N = 154)	GC+P (N = 149)
Sex								
Male	21 (43.0)	23 (48.0)	41 (59.0)	51 (76.0)	33 (46.0)	37 (51.0)	99 (64.0)	100 (67.0)
Female	28 (57.0)	25 (52.0)	28 (41.0)	16 (24)	39 (54.0)	35 (49.0)	55 (36.0)	49 (33.0)
Median age, ye	57.0	56.0	55.0	58.0	58.0	55.0	58.0	57.0
ECOG PS								
0	13 (27.0)	12 (26.0)	21 (30.0)	17 (25.0)	18 (25.0)	20 (28.0)	41 (27.0)	39 (26.0)
1	36 (73.0)	35 (74.0)	48 (70.0)	50 (75.0)	54 (75.0)	51 (72.0)	113 (73.0)	110 (74.0)
Missing	1 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)	0 (0.0)
Smoking status								
Current	8 (16.0)	7 (15.0)	22 (32.0)	26 (39.0)	11 (15.0)	11 (15.0)	54 (35.0)	52 (35.0)
Former	6 (12.0)	8 (17.0)	17 (25.0)	20 (30.0)	13 (18.0)	13 (18.0)	36 (23.0)	39 (26.0)
Never	35 (71.0)	33 (69.0)	30 (43.0)	21 (31.0)	48 (67.0)	48 (67.0)	64 (42.0)	58 (39.0)
Disease stage								
IIIb	1 (2.0)	2 (4.0)	11 (16.0)	8 (12.0)	2 (3.0)	2 (3.0)	19 (12.0)	21 (14.0)
IV	48 (98.0)	46 (96.0)	58 (84.0)	59 (88.0)	70 (97.0)	70 (97.0)	135 (88.0)	128 (86.0)
Histology								
Adenocarcinoma	45 (92.0)	44 (92.0)	48 (70.0)	45 (67.0)	65 (90.0)	62 (86.0)	109 (71.0)	104 (70.0)
Other	4 (8.0)	4 (8.0)	21 (30.0)	22 (33.0)	7 (10.0)	10 (14.0)	45 (29.0)	45 (30.0)

NOTE: Of the 241 tumor samples available at baseline, eight had single resistance mutations, which were not counted as *EGFR* mutation positive or negative. Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.

of which was used for *EGFR* mutation detection. Both the tissue and blood tests detect 41 *EGFR* mutations (including G719A/S/C in exon 18, deletions and complex mutations in exon 19, S768I, T790M, and exon 20 insertions, and L858R in exon 21).

The detection limit of copy number for each mutation was determined using minigenes carrying each mutation titrated into wild-type genomic background DNA in a range of 0.25 ng to 500 ng (82–167,000 copies). The different mutation assays are of comparable sensitivity under ideal experimental conditions and can reliably detect mutant alleles within a range of 0.1% to 1.0% (data not shown). A standard curve model using the internal control Cp genomic DNA was used to determine DNA concentration and copy number. To be classified as *EGFR* mutation positive for this analysis, at least one activating mutation (exon 19 deletion, L858R, G719x, or L861Q) had to be identified in a sample.

Statistical analysis

The primary objective of this exploratory analysis was to assess the diagnostic utility of the blood test for sensitivity, specificity, positive predictive value, negative predictive value, concordance rate, and comparison with tumor tissue *EGFR* mutation status, as assessed by the FPET assay. Using matched tissue and plasma samples, concordance rate was calculated as the number of samples positive in both tissue and plasma, plus the number of samples negative in both tissue and plasma, out of the total number of matched samples. Sensitivity was calculated as the number of samples positive in both tissue and plasma out of the positive tissue samples, whereas specificity was calculated from the number of plasma- and tissue-negative samples out of the total negative tissue samples. Positive predictive value was the tissue- and plasma-positive rate in positive plasma samples and negative predictive value was the tissue- and plasma-negative rate in the negative plasma samples. Secondary objectives included: assessing the predictive value of baseline cfDNA *EGFR* mutations on treatment outcomes in FASTACT-2, including PFS, OS, and objective response rate (ORR); evaluating the clinical utility of

measuring dynamic changes in cfDNA *EGFR* mutation allele copy number at baseline, C3 and PD; and exploring the predictive value of C3 cfDNA *EGFR* mutation status in terms of treatment outcomes. The predictive value of C3 cfDNA *EGFR* mutation status was explored using a subset of patients who were both cfDNA *EGFR* positive at baseline and had valid C3 cfDNA *EGFR* results. The requirement of C3 cfDNA results meant that patients withdrawing before C3 were not included in this analysis. The clinical outcomes for PFS and OS with all patients combined (erlotinib and placebo pooled) and erlotinib-treated patients only were evaluated for the C3 analysis.


FASTACT-2 was powered for clinical endpoints (PFS), not for biomarker analyses. Kaplan–Meier methodology was used for analysis of PFS and OS by biomarker status; logistic regression was used to assess ORR.

Results

At baseline, 241 tissue samples (from 53.4% of patients) and 447 blood samples (99.1% of patients) were available for analysis. Baseline clinical characteristics stratified by mutation status and therapy were well balanced between treatment groups (Table 1).

Of the tissue and blood samples, there were a total of 238 matched samples. At C3, 362 blood samples were available for analysis and at PD, 376 blood samples were available. In all, 305 patients (67.6%) had blood-based results at all three time points (Fig. 1). Overall concordance between blood and tissue samples at baseline was 88% (209/238; Table 2). Sensitivity and specificity were 75% (72/96) and 96% (137/142), respectively. The positive predictive value was 94% (72/77) and the negative predictive value was 85% (137/161). In total, five cases were *EGFR* mutation positive in blood samples but *EGFR* mutation negative in the corresponding tissue sample, whereas 24 cases were mutation positive in tissue and mutation negative in blood samples. Mutation-specific concordance was 94.5% for exon 19 deletions, 93.3% for L858R mutations, 99.6% for G719x, and 100% for

Figure 1.
Sample availability for tumor and blood-based *EGFR* mutation analysis.



L861Q (Supplementary Table S1). Sensitivity was 82.5% for exon 19 deletions, 62.2% for L858R, 50% for G719x, and 100% for L861Q; specificity was 98.3%, 99%, 100%, and 100%, respectively. The number of tissue-positive G719x and L861Q mutations were very low ($n = 2$ and $n = 1$, respectively) which makes the sensitivity estimates highly variable.

Of the 241 tissue samples at baseline, 105 (43.5%) were confirmed to harbor *EGFR* mutations and the most common mutations identified were exon 19 deletions only (56/105; 53.3%) and L858R mutations only (33/105; 31.4%; Supplementary Table S2). The frequency of *EGFR* mutation detection was similar in the baseline blood samples. *EGFR* mutation types in the 238 matched samples are shown in Supplementary Table S3.

Predictive power of cfDNA *EGFR* mutations

The cfDNA *EGFR* mutation-positive (mut^+) subgroup ($n = 144$) had a median PFS of 13.1 months versus 6.0 months for erlotinib and placebo arms, respectively [HR, 0.22; 95% confidence interval (CI), 0.14–0.33, $P < 0.0001$; Supplementary Fig. S1A), with median OS of 29.3 months and 18.8 months, respectively (HR, 0.54; 95% CI, 0.35–0.83, $P = 0.0044$; Supplementary Fig. S1B). Similar results were obtained from the analysis of tissue *EGFR* mutation-positive status (21).

Table 2. Concordance between tumor and cfDNA mutation results at baseline

EGFR TKI-sensitive mutations	cfDNA <i>EGFR</i> mut^+	cfDNA <i>EGFR</i> mut^-	Total
Tumor tissue <i>EGFR</i> mut^+	72	24	96
Tumor tissue <i>EGFR</i> mut^-	5	137	142
Total	77	161	238

NOTE: For concordance calculations only, single resistant mutations found in the tumor were counted as mutation negative.

The median PFS from the cfDNA analyses (13.1 months) compared with the previously reported tissue-based analysis (16.8 months) suggested that there may be less benefit with erlotinib treatment for patients with blood-only samples, therefore efficacy in the subgroup that only had cfDNA-based *EGFR* mut^+ status was assessed. Median PFS was 12.8 versus 6.0 months for erlotinib ($n = 31$) and placebo ($n = 36$), respectively (HR, 0.25; 95% CI, 0.14–0.47, $P < 0.0001$; Supplementary Fig. S1C); median OS was 29.3 versus 21.4 months, respectively (HR, 0.59; 95% CI, 0.30–1.15, $P = 0.1202$; Supplementary Fig. S1D). Baseline characteristics in *EGFR* mut^+ subgroups (cfDNA-only samples) are shown in Supplementary Table S4.

In the cfDNA *EGFR* mutation-negative (mut^-) group ($n = 303$), median PFS was reported as 6.2 months for erlotinib versus 6.1 months for placebo (HR, 0.83; 95% CI, 0.65–1.04, $P = 0.1076$; Supplementary Fig. S1E), with median OS of 15.3 months and 13.6 months for erlotinib and placebo, respectively (HR, 0.94; 95% CI, 0.72–1.22, $P = 0.6449$; Supplementary Fig. S1F). Again, tissue-based analysis resulted in similar outcomes (21). Therefore, *EGFR* mutation status defined by blood-based cfDNA analysis appears to produce similar results to tissue-based assessment in terms of predicting outcomes. In those with only blood-based samples available, cfDNA mut^- status resulted in median PFS of 5.5 months for erlotinib and 5.9 months for placebo (HR, 0.85; 95% CI, 0.60–1.19, $P = 0.3398$; Supplementary Fig. S1G) and median OS of 13.0 months and 13.6 months, respectively (HR, 1.07; 95% CI, 0.73–1.56, $P = 0.7387$; Supplementary Fig. S1H).

Dynamic changes in cfDNA *EGFR* mutations

Dynamic changes in *EGFR* mut^+ cfDNA levels at baseline, C3, and PD are shown in Fig. 2. Total *EGFR* mutation-specific cfDNA levels decreased at C3 and returned at time of PD. There were fewer mutant *EGFR* alleles at both the C3 and PD time points in samples derived from patients in the erlotinib arm compared with the

Downloaded from <http://aacrjournals.org/clinccancerres/article-pdf/21/14/3199/202610713196.pdf> by guest on 28 February 2024




Figure 2. Dynamic quantitative change in *EGFR* mut⁺ cfDNA at baseline, C3, and PD. GC+E, erlotinib plus chemotherapy; GC+P, placebo plus chemotherapy. ^acopy/mL ≤ 0.1 were undetectable.

Median <i>EGFR</i> mut ⁺ cfDNA (copy/mL of blood)	GC+P	GC+E
Baseline	78	94
C3	5	0
PD	83	6

placebo arm (C3 medians: 0 copy/mL for erlotinib, 5 for placebo; PD medians: 6 copy/mL for erlotinib, 83 for placebo).

Although the small sample size should be noted, in patients with cfDNA *EGFR* mut⁺ status at baseline, ORR was lower in patients whose cfDNA samples remained *EGFR* mut⁺ at C3 (33%, 14/42) compared with patients whose cfDNA samples registered as *EGFR* mut⁻ (66%, 53/80) at C3. When assessed in patients from the erlotinib and chemotherapy combination arm only, ORR was 67% (6/9) for those with cfDNA *EGFR* mut⁻ samples at C3 and 83% (47/57) for those with cfDNA *EGFR* mut⁺ samples at C3 (Table 3).

Treatment outcomes were also assessed in all patients (erlotinib and placebo arms combined) who were cfDNA mut⁺ at baseline, according to C3 cfDNA *EGFR* mutation status. Median PFS for patients who continued to have detectable mutant *EGFR* alleles at C3 was 7.2 months versus 12.0 months for patients with no detectable mutant alleles (HR, 0.32; 95% CI, 0.21–0.48, $P < 0.0001$; Fig. 3A). Similarly, median OS for patients who continued to have detectable *EGFR* mutations at C3 was 18.2 months, whereas for patients without detectable mutations median OS was 31.9 months (HR, 0.51; 95% CI, 0.31–0.84, $P = 0.0066$). Patients in the erlotinib arm only were further analyzed: cfDNA *EGFR* mut⁻ status at C3 was associated with significantly improved PFS (HR, 0.38; $P = 0.0083$) and numerically longer OS (HR, 0.45; $P = 0.0831$) compared with patients whose cfDNA was *EGFR* mut⁺ at C3 (Fig. 3B). In the placebo arm, cfDNA *EGFR* mut⁻ status at C3 resulted in numerically longer PFS (HR, 0.64; $P = 0.1112$) and OS (HR, 0.71; $P = 0.3325$) versus patients with cfDNA *EGFR* mut⁺ status at C3.

Discussion

To our knowledge, this is the first study to demonstrate the predictive value of baseline and C3 cfDNA *EGFR* mutation status in blood in a phase III, randomized, controlled study. In this study, blood-based testing for *EGFR* activating mutations was relatively sensitive (75%) and highly specific (96%), with high concordance between matched blood-based and tumor tissue samples (88%), suggesting that a blood-based assay may have utility in clinical practice. Concordance was $>90\%$ for specific mutations when analyzed separately; however, sample size for the G719X and L861Q subsets was too small for adequate individual analysis. Reasons for the relatively low sensitivity in detection of L858R are unclear. This should be further investigated in a larger trial and possibly with an alternative technology such as Digital PCR.

A number of prior studies have investigated the use of cfDNA for the assessment of *EGFR* mutation status with varying results. The variation in concordance and detection rates of these different methods highlights the need for a sensitive, standardized method for blood-based testing. Results of the current study suggest that cfDNA *EGFR* mutation analysis is a potential alternative testing method for those patients from whom a tumor tissue sample cannot be obtained. This approach may also enable faster turnaround for molecular diagnosis in the first-line setting, and could be used as an initial screening tool for earlier diagnosis alongside current tissue-based approaches. Patients usually present with a radiologic image suggestive of primary bronchogenic carcinoma. The standard course of action with the suspicion of lung cancer

Table 3. Efficacy outcomes for baseline cfDNA mut⁺ patients by C3 cfDNA mutation status

C3	ORR, %	Median PFS, mo	Median OS, mo
<i>EGFR</i> mut ⁺			
GC+P ($n = 33$)	24.2	6.8	18.8
GC+E ($n = 9$)	66.7	7.8	17.7
	OR, 6.25 (95% CI, 1.26–30.90)	HR, 0.38 (95% CI, 0.17–0.90)	HR, 0.98 (95% CI, 0.40–2.42)
<i>EGFR</i> mut ⁻			
GC+P ($n = 23$)	26.1	7.8	26.3
GC+E ($n = 57$)	82.5	16.6	32.4
	OR, 13.32 (95% CI, 4.20–42.23)	HR, 0.23 (95% CI, 0.13–0.41)	HR, 0.61 (95% CI, 0.31–1.21)




Figure 3. PFS and OS for baseline cfDNA mut⁺ patients stratified by C3 cfDNA *EGFR* mutation status in both treatment arms combined (A) and in the GE+E arm only (B).

includes bronchoscopy and/or needle biopsy and pathologic evaluation before sending out for molecular testing. With the blood test concordance of 88%, molecular analysis could be performed much earlier and be accurate in three out of four patients.

This analysis reported 24 false-negative cases and five potentially false-positive cases. This could lead to the potential risk of inappropriate selection of patients for first-line treatment, although it is also possible that the tissue result was misleading due to selection bias of the biopsied lesion. Of the five false-positive cases, three received erlotinib plus chemotherapy and had best overall responses of stable disease ($n = 2$) and partial response ($n = 1$); PFS in these 3 patients was 7.2, 12.7, and 5.5 months, respectively, and OS was 9.1, 21.6, and 18.1 months, respectively. Of the false-negative cases, 11 received erlotinib and had median PFS of 19.1 months, and median OS of 31.4 months. Because of the nature of the study design, it cannot be confirmed whether these were true false-positive or false-negative cases. The observation that the blood result differed from the tissue result may be explained by the heterogeneous nature of NSCLC tumor biology (23). Presuming the presence of both *EGFR* mut⁺ and

mut⁻ tumor tissue in a patient, their cfDNA could test positive, while a biopsy of primarily *EGFR* mut⁻ tissue would show the contrary result. This question might be resolved in the future by multiple tumor sampling and/or clinical correlation of tumor response to single-agent *EGFR* TKI.

Total *EGFR* mutation-specific cfDNA levels decreased at C3 and returned at time of PD, which may be due to changes in tumor volume or increased metastases (24). Larger tumor volume or more metastatic tumors may provide more DNA to "leak" from the necrotic tumor into the bloodstream, resulting in higher DNA levels. Finding fewer *EGFR*-mutant alleles in the erlotinib arm at the C3 timepoint is consistent with the mode of action of erlotinib, in inhibiting *EGFR*-mutant tumor cells. Serial quantitative measurement of *EGFR* mut⁺ cfDNA could therefore be an alternative method to assess tumor progression. Limited by infrequent sampling, small sample size, and use of combination therapy, our current study results may only establish the feasibility for future prospective studies.

Median PFS with first-line *EGFR* TKIs in patients with *EGFR* mutations ranges from 9.2 to 14.0 months, but not all patients benefit equally (1, 3, 4, 5). Genomic markers such as BIM

polymorphisms are predictive of shorter PFS in patients treated with first-line EGFR TKIs (25). cfDNA *EGFR* mutation status at C3 could offer another simple predictive biomarker of outcomes before eventual radiologic progression. The complete disappearance of *EGFR* mutations in cfDNA is reminiscent of the molecular remission of Philadelphia chromosome in patients with chronic myeloid leukemia (26). cfDNA *EGFR* mut⁺ status at C3 was predictive of worse PFS and OS. Again, this could be linked to the change in tumor burden or increased metastases, as this may be associated with worse survival outcomes. Leduc and colleagues reported significant reductions in PFS with increasing tumor volume in patients with *EGFR* mut⁺ disease receiving EGFR TKIs (27). Median PFS for tumor volume <35cc, 35 to 74cc, and >74cc was 9 months, 8 months, and 7.3 months, respectively ($P = 0.04$). A future study correlating serial blood-based *EGFR* mutation status with tumor volume is warranted.

Key questions to address in any future trials would include what a treatment algorithm would look like based on dynamic change in cfDNA *EGFR* status; for example, whether baseline cfDNA mut⁺ and C3 cfDNA mut⁺ status without radiologic progression should result in a change of treatment, such as the addition of another agent or a switch to another regimen.

The limitations of the study must be noted when interpreting this analysis, including the exploratory nature of these results and the small sample size, particularly in the C3 analysis ($n = 66$ for the erlotinib arm). In addition, although the control arm of this study was standard chemotherapy, a total of 85% of patients in the chemotherapy arm received TKI therapy as second-line treatment, which likely impacted OS. One limitation of the efficacy analysis is that different mutation types (exon 19 deletions, L858R, G719X, or L861Q) were all classed together as "EGFR mutation-positive." It would be interesting to see how efficacy correlated with specific plasma mutations; however, a study adequately powered for such comparisons would be needed for this analysis.

Patients who are able to contribute only cfDNA samples rather than tissue samples represent a significant unmet medical need. After further validation, blood-based detection of *EGFR* mutations could be utilized for patients too sick to undergo biopsies, those with tumors unsuitable for biopsy, or in cases where access to appropriate medical facilities is limited.

Conclusions

Use of blood-based cfDNA for *EGFR* mutation analysis is feasible and the PCR-based assay offers a sensitive and highly specific test with potential clinical application. C3 cfDNA *EGFR* mutation status is potentially predictive of clinical outcomes and warrants further investigation in a prospective study.

References

- Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947–57.
- Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated *EGFR*. *N Engl J Med* 2010;362:2380–8.
- Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor

Disclosure of Potential Conflicts of Interest

T.S.K. Mok reports receiving speakers bureau honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Serono, Pfizer, and Roche/Genentech; and is a consultant/advisory board member for AstraZeneca, BiMarin, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Janssen, Merck Serono, Novartis, Pfizer, and Roche/Genentech. Y.-L. Wu is a consultant/advisory board member for MSD. J. Tsai is an inventor on a patent application for blood mutation detection. M. Truman has ownership interest (including patents) and is a consultant/advisory board member for Roche Products Ltd. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: T. Mok, Y.-L. Wu, J.S. Lee, S. Thongprasert, M. Truman, B. Klughammer

Development of methodology: T. Mok, Y.-L. Wu, J.S. Lee, S. Thongprasert, C. Zhou, W. Wen, J. Tsai, M. Truman, B. Klughammer, L. Wu

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T. Mok, Y.-L. Wu, C.-J. Yu, V. Sriuranpong, J. Sandoval-Tan, G. Ladrera, S. Thongprasert, V. Srimuninnimit, M. Liao, Y. Zhu, C. Zhou, F. Fuerte, B. Margono, M. Truman, B. Klughammer

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Mok, Y.-L. Wu, J.S. Lee, S. Thongprasert, C. Zhou, W. Wen, J. Tsai, M. Truman, B. Klughammer, D.S. Shames

Writing, review, and/or revision of the manuscript: T. Mok, Y.-L. Wu, J.S. Lee, C.-J. Yu, V. Sriuranpong, J. Sandoval-Tan, S. Thongprasert, V. Srimuninnimit, M. Liao, C. Zhou, F. Fuerte, B. Margono, W. Wen, M. Truman, B. Klughammer, D.S. Shames

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): W. Wen, M. Truman, B. Klughammer

Study supervision: T. Mok, Y.-L. Wu, S. Thongprasert, C. Zhou, B. Klughammer

Other (final approval of manuscript): J. Tsai

Acknowledgments

The authors thank Kate Jin and Kerstin Trunzer for their valuable effort in encouraging the collection of the plasma samples, without which these analyses would not be possible.

Grant Support

This work was designed, funded, and monitored by F. Hoffmann-La Roche. Biomarker analysis was carried out by Roche Molecular Systems. Data were collected by F. Hoffmann-La Roche and all analysis and interpretation of the data was carried out by the authors, investigators, F. Hoffmann-La Roche and Roche Molecular Systems. Third-party medical writing assistance from Joanna Musgrove of Gardiner-Caldwell Communications was funded by F. Hoffmann-La Roche.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 8, 2014; revised February 25, 2015; accepted February 28, 2015; published OnlineFirst March 31, 2015.

(WJTOG3405): an open-label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121–8.

- Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced *EGFR* mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 2011;12:735–42.
- Rosell R, Carcerency E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European

- patients with advanced *EGFR* mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012;13:239–46.
6. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: First-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. *J Clin Oncol* 2012; 30:1122–8.
 7. Sequist L, Yang J, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with *EGFR* mutations. *J Clin Oncol* 2013;31:3327–34.
 8. Paz-Ares L, Soulieres D, Moecks J, Bara I, Mok T, Klughammer B. Pooled analysis of clinical outcomes for *EGFR* TKI-treated patients with *EGFR* mutation-positive NSCLC. *J Cell Mol Med* 2014;18:1519–39.
 9. Wu YL, Zhou C, Hu C, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring *EGFR* mutations (LUX-Lung 6): an open-label randomized phase 3 trial. *Lancet Oncol* 2014;15:213–22.
 10. Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. *Lung Cancer* 2012;77:371–5.
 11. Xu C, Zhou Q, Wu YL. Can *EGFR* TKIs be used in first-line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? A literature-based meta-analysis. *J Haematol Oncol* 2012; 5:62–77.
 12. Newman A, Bratman S, To J, Wynne JF, Eclow NC, Modlin LA, et al. An ultra sensitive method for quantitating circulating tumour DNA with broad patient coverage. *Nat Med* 2014;20:548–54.
 13. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumour response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. *J Clin Oncol* 2009;27:2653–9.
 14. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). *Br J Cancer* 2007; 97:778–84.
 15. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum. *J Thorac Oncol* 2012;7:115–21.
 16. Douillard J, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in *EGFR* Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of *EGFR* status. *J Thoracic Oncol* 2014;9:1345–53.
 17. Kim H, Lee S, Hyun D, Lee MK, Lee HK, Choi CM, et al. Detection of *EGFR* mutations in circulating free DNA by PNA-mediated PCR clamping. *J Exp Clin Cancer Res* 2013;32:50.
 18. Courard S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanche H, et al. Non invasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. *Clin Cancer Res* 2014;20: 4613–24.
 19. Oxnard G, Paweletz G, Kuang Y, Mach S, O'Connell A, Messineo M, et al. Noninvasive detection of response and resistance in *EGFR*-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. *Clin Cancer Res* 2014;20:1698–705.
 20. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. *J Clin Oncol* 2009;27:5080–7.
 21. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. *Lancet Oncol* 2013;14:777–86.
 22. Weber B, Meldgaard P, Hager H, Wu L, Wei W, Tsai J, et al. Detection of *EGFR* mutations in plasma and biopsies from non-small-cell lung cancer patients by allele-specific PCR assays. *BMC Cancer* 2014;14:294.
 23. An S, Chen Z, Su J, Zhang XC, Zhong WZ, Yang JJ, et al. Identification of enriched driver gene alterations in subgroups of non-small-cell lung cancer patients based on histology and smoking status. *PLoS ONE* 2012;7:e40109.
 24. Kamat A, Bischoff F, Dang D, Baldwin MF, Han LY, Lin YG, et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. *Cancer Biol Ther* 2006;5:1369–74.
 25. Ng K, Hillmer A, Chuah C, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. *Nat Med* 2012;18: 521–8.
 26. Bottcher S, Ritgeb M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. *J Clin Oncol* 2012;30:980–8.
 27. Leduc C, Moussa N, Faivre L, Biondani P, Pignon J, Caramella C, et al. Tumour burden and tyrosine kinase inhibitors (TKI) benefit in advanced non-small-cell lung cancer (NSCLC) patients with *EGFR* sensitizing mutations (m*EGFR*) and *ALK* rearrangement (*ALK+*) [abstract 920]. *J Thorac Oncol* 2014;9:S37.